BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Apple Restores Telegram to App Store After Content Policy Violation 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
| Montrouge, April 3, 2018 |
DBV Technologies to Attend the 11th Kempen Life Sciences Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief Business Officer, will host investor meetings during the 11th Kempen Life Sciences Conference on Wednesday, April 18, 2018 at the Kempen & Co offices in Amsterdam, Netherlands.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
[email protected]
DBV Media Contact
Roberta Di Giorgio
Senior Director, Corporate Communications
+1 917-612-2861
[email protected]
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c85aa08f-22a4-4152-9093-3a2d4bc72c27
